Hepatitis B virus carriers without precore mutations in hepatitis B e antigen-negative stage show more severe liver damage

被引:89
作者
Lindh, M
Horal, P
Dhillon, AP
Furuta, Y
Norkrans, G
机构
[1] GOTHENBURG UNIV, DEPT INFECT DIS, S-41346 GOTHENBURG, SWEDEN
[2] ROYAL FREE HOSP, DEPT HISTOPATHOL, LONDON NW3 2QG, ENGLAND
关键词
D O I
10.1002/hep.510240305
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis B e antigen (HBeAg) is considered to be a major target for the immune response in chronic hepatitis B. The G --> A mutation at nucleotide 1896 may mediate viral escape by creating a TAG stop codon in the precore region, thus preventing HBeAg production, This mutation frequently evolves during HBe seroconversion if thymine, but rarely if cytosine, is present in position 1858. Applying a combination of polymerase chain reaction (PCR) and restriction enzyme action, we have studied the relation of the TAG mutation and the nucleotide (nt) 1858 variants to liver damage assessed by histology activity index (HAI) scoring in 175 chronic hepatitis B virus (HBV) carriers, A TAG mutation was found in 68 of 71 (96%) of HBeAg-negative carriers infected with a T-1858 strain, but not in any of 33 carriers infected exclusively with a C-1858 strain, Four patients Showed a mutation of the precore start codon, and 2 had a TAA stop mutation at codon 2. HBeAg-positive infection with a mixture of wild-type and TAG mutant virus indicated active liver damage, because 8 of 9 (89%) of such patients had a Knodell HAI greater than or equal to 8. In HBeAg-negative stage, both inflammation and fibrosis were more pronounced in carriers infected with wild-type HBV compared with pre core mutants, C-1858 strains were associated with more inflammation and fibrosis compared with T-1858 strains, C-1858 strains were found in 71% of northern European, 17% of southern European, 31% of African, 2% of Middle Eastern, and 10% of Far Eastern carriers. Analysis of these variants and mutants may prove useful for clinical evaluation and choice of therapy, and may be facilitated by the methods described.
引用
收藏
页码:494 / 501
页数:8
相关论文
共 51 条
  • [1] AKARCA US, 1994, HEPATOLOGY, V19, P1366
  • [2] ANGUS PW, 1995, HEPATOLOGY, V21, P14, DOI 10.1016/0270-9139(95)90401-8
  • [3] BARNABA V, 1994, J IMMUNOL, V152, P3074
  • [4] NATURALLY-OCCURRING MISSENSE MUTATION IN THE POLYMERASE GENE TERMINATING HEPATITIS-B VIRUS-REPLICATION
    BLUM, HE
    GALUN, E
    LIANG, TJ
    VONWEIZSACKER, F
    WANDS, JR
    [J]. JOURNAL OF VIROLOGY, 1991, 65 (04) : 1836 - 1842
  • [5] A NEW HEPATITIS-B VIRUS-STRAIN IN PATIENTS WITH SEVERE ANTI-HBE POSITIVE CHRONIC HEPATITIS-B
    BRUNETTO, MR
    STEMLER, M
    BONINO, F
    SCHODEL, F
    OLIVERI, F
    RIZZETTO, M
    VERME, G
    WILL, H
    [J]. JOURNAL OF HEPATOLOGY, 1990, 10 (02) : 258 - 261
  • [6] BRUNETTO MR, 1989, ITAL J GASTROENTEROL, V21, P151
  • [7] HEPATITIS-B VIRUS UNABLE TO SECRETE E-ANTIGEN AND RESPONSE TO INTERFERON IN CHRONIC HEPATITIS-B
    BRUNETTO, MR
    GIARIN, M
    SARACCO, G
    OLIVERI, F
    CALVO, P
    CAPRA, G
    RANDONE, A
    ABATE, ML
    MANZINI, P
    CAPALBO, M
    PIANTINO, P
    VERME, G
    BONINO, F
    [J]. GASTROENTEROLOGY, 1993, 105 (03) : 845 - 850
  • [8] CARMAN WF, 1989, LANCET, V2, P588
  • [9] CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333
  • [10] ANALYSIS OF WILD-TYPE AND E-ANTIGEN-DEFECTIVE HEPATITIS-B VIRUSES DURING THE COURSE OF A SHORT-TERM CORTICOSTEROID-THERAPY IN CHRONIC HEPATITIS-B
    DAIKOKU, M
    NAKATA, K
    HAMASAKI, K
    IDO, A
    NAKAO, K
    KATO, YJ
    KOGA, M
    YANO, M
    NAGATAKI, S
    [J]. JOURNAL OF MEDICAL VIROLOGY, 1995, 47 (02) : 184 - 188